Acute Myeloid Leukemia
Acute Myeloid Leukemia
The latest news, research, and perspectives in acute myeloid leukemia (AML). AML, an aggressive blood cancer, is the most common type of acute leukemia in adults and most often develops when myeloid cells that normally develop into the various types of mature blood cells instead form abnormal myeloblasts.
Advertisement
Blood Cancer TalksBlood Cancer Talks | November 21, 2023
Alexander Perl, MD, joins the hosts to discuss the management of newly diagnosed and relapsed FLT3-positive AML.
Listen Now
Melissa BadamoAcute Myeloid Leukemia | November 14, 2023
Early deaths remain a barrier against understanding a cure-for-all.
Melissa BadamoAcute Myeloid Leukemia | November 14, 2023
Researchers found that sabatolimab at 400 mg and 800 mg were well tolerated, as cytopenias occurred at low rates.
Melissa BadamoAcute Myeloid Leukemia | November 13, 2023
All response-evaluable patients attained a morphologic remission, translating into a 100% overall response rate.
Cecilia BrownPrint | November 10, 2023
Dr. Tasian discusses the path that took her to the best job in the world, silver linings along the way, and more.
Jerald Radich, MDAcute Myeloid Leukemia | November 9, 2023
This editorial outlines treatments for relapsed AML, T-Cell activation, and more.
Advertisement
Melissa BadamoAcute Myeloid Leukemia | November 3, 2023
RNA sequencing showed decreased gene expression levels of the NF-κB target genes IL1β and IER3 after emavusertib treatment.
Cecilia BrownAcute Myeloid Leukemia | October 11, 2023
The study included 815 patients with AML who were “unfit to receive intensive induction chemotherapy."
Cecilia BrownAcute Myeloid Leukemia | October 11, 2023
Mutations in IDH were “strongly correlated with increased age,” according to the study’s authors.
Cecilia BrownAcute Myeloid Leukemia | September 21, 2023
The study was conducted because it was “uncertain whether a fractionated schedule provides additional benefit."
Cecilia BrownAcute Myeloid Leukemia | September 21, 2023
Researchers analyzed prognostic impact of NPM1 MRD in a real-world cohort of patients with NPM1-mutated AML.
Cecilia BrownAcute Myeloid Leukemia | September 21, 2023
The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population.
Cecilia BrownAcute Myeloid Leukemia | September 20, 2023
The retrospective, observational study included adults who received their first allogeneic HSCT during their first remission.
Rami Komrokji, MDAcute Myeloid Leukemia | September 12, 2023
The crew talk about AML and MDS in this episode of The HemOnc Pulse.
Chadi Nabhan, MD, MBA, FACPAcute Myeloid Leukemia | September 11, 2023
Dr. Erba answers this question and more in this interview with Dr. Chadi Nabhan.
Chadi Nabhan, MD, MBA, FACPMeeting News | September 10, 2023
Dr. Nath spoke transplant in patients with AML who are elderly and emphasized the need to include them in clinical trials.
Leah SherwoodAcute Myeloid Leukemia | September 8, 2023
Enrolled patients must be aged 75 years or older or aged 18-74 years with specific comorbidities.
Leah SherwoodMeeting News | September 8, 2023
The trial will enroll approximately 346 patients with treatment-naive TP53-mutated disease or biallelic 17p deletions.
Marina Konopleva, MD, PhDMeeting News | September 8, 2023
Dr. Konopleva explains the controversy and what she sees on the horizon for MRD in AML.
Cecilia BrownMeeting News | September 7, 2023
The award recognizes a SOHO member who has significantly contributed to the advancement of blood cancer care and research.
Advertisement
Advertisement
Editorial Board